TY - PAT
T1 - LIVE-ATTENUATED COMPOSITIONS FOR BACTERIAL INFECTIONS
AU - Schaeffer, Anthony
AU - Klumpp, David
N1 - filingdate: 2011-10-26
issueddate: 2014-4-29
Status: published
attorneydocketnumber: 2008-004-03
PY - 2012/4/19
Y1 - 2012/4/19
N2 - A Live-Attenuated Vaccine for Urinary Tract and Other Bacterial Infections
NU 2008-004
Inventors
Anthony J. Schaeffer*
David J. Klumpp
Benjamin Billips
Abstract
Urinary tract infections, either chronic or acute, are a frequent health problem in a variety of populations. Northwestern investigators have demonstrated that deletion of a certain gene from urinary-tract colonizing bacteria has resulted in a strain that promotes immune response when administered to mammalian subjects. The modified bacterium does not establish a persistent population in the bladder, but promotes cytokine secretion from urothelial cells. These bacteria represent a candidate material for a live-attenuated vaccine that could be used to protect against acute and recurrent urinary tract infections. Successful tests have been performed in a mouse model.
Applications
o Preventative medicine for UTIs
o Alternative to repeated use of antibiotics
o Particularly useful for nursing home patients or other high-risk groups
Advantages
o Prevents infection by stimulating patient immune system
o Inexpensive, easy-to-grow bacterium
o Simple to administer
Publications
Billips, B. Yaggie, R. Cashy, J. Schaeffer, A. Klumpp, D. (2009) A Live-Attenuated Vaccine for the Treatment of Urinary Tract Infection by Uropathogenic Escherichia Coli. The Journal of Infectious Diseases. 200(2): 263-272.
IP Status
A patent application has been filed.
Marketing Contact
Michael Moore, PhD
Invention Manager
(p) 847-491-4645
(e) michaelmoore@northwestern.edu
AB - A Live-Attenuated Vaccine for Urinary Tract and Other Bacterial Infections
NU 2008-004
Inventors
Anthony J. Schaeffer*
David J. Klumpp
Benjamin Billips
Abstract
Urinary tract infections, either chronic or acute, are a frequent health problem in a variety of populations. Northwestern investigators have demonstrated that deletion of a certain gene from urinary-tract colonizing bacteria has resulted in a strain that promotes immune response when administered to mammalian subjects. The modified bacterium does not establish a persistent population in the bladder, but promotes cytokine secretion from urothelial cells. These bacteria represent a candidate material for a live-attenuated vaccine that could be used to protect against acute and recurrent urinary tract infections. Successful tests have been performed in a mouse model.
Applications
o Preventative medicine for UTIs
o Alternative to repeated use of antibiotics
o Particularly useful for nursing home patients or other high-risk groups
Advantages
o Prevents infection by stimulating patient immune system
o Inexpensive, easy-to-grow bacterium
o Simple to administer
Publications
Billips, B. Yaggie, R. Cashy, J. Schaeffer, A. Klumpp, D. (2009) A Live-Attenuated Vaccine for the Treatment of Urinary Tract Infection by Uropathogenic Escherichia Coli. The Journal of Infectious Diseases. 200(2): 263-272.
IP Status
A patent application has been filed.
Marketing Contact
Michael Moore, PhD
Invention Manager
(p) 847-491-4645
(e) michaelmoore@northwestern.edu
M3 - Patent
M1 - 8709444
ER -
